Cosignity Ltd

Cosignity Ltd develops AI-powered digital biomarkers from speech and sleep data to enable early detection and continuous monitoring of mental and neurological health conditions.

Problem

Early signs of cognitive decline and mood disorders often go unnoticed until they significantly impact daily life. Traditional assessments are costly, subjective, and infrequent, while current digital tools lack clinical precision and personalisation. 

Solution 

Cosignity develops scientifically validated digital biomarkers that use speech and sleep data to detect and monitor mental and neurological health changes continuously and non-invasively.

Contact

Fasih Haider